
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax SA has reported promising findings from its Phase 2 trials for the drug candidate obefazimod, indicating significant improvements in average change from baseline in key metrics, which supports a strong foundation for its ongoing Phase 3 clinical trials for ulcerative colitis. The drug demonstrates compelling efficacy and a favorable safety profile, positioning it as a potential early treatment option prioritized over current advanced therapies for inflammatory bowel diseases. Confidence in the success of the upcoming ABTECT Phase 3 trial stems from its strong Phase 2 results, indicating a robust potential for clinical adoption and market acceptance in the treatment of chronic inflammatory diseases.
Bears say
Abivax SA has a history of sustained financial losses and has yet to achieve profitability, which presents significant concerns regarding its long-term viability. The company faces several risks, including potential failure in meeting crucial efficacy endpoints in clinical trials, regulatory challenges, and complications in securing acceptable partnerships that could jeopardize future commercial launches. Additionally, litigation risks and potential market conditions may hinder the successful commercialization of its candidates, further exacerbating the risks to its financial outlook.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares